Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
QuintilesIMS
Chubb
Healthtrust
Farmers Insurance
UBS

Generated: September 17, 2019

DrugPatentWatch Database Preview

Patent: 10,144,779

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,144,779
Title:Anti-CTLA-4 antibodies and methods of use thereof
Abstract: The instant disclosure provides antibodies that specifically bind to human CTLA-4 and antagonize CTLA-4 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
Inventor(s): van Dijk; Marc (Bosch en Duin, NL), Mundt; Cornelia Anne (Lorrach, DE), Ritter; Gerd (New York, NY), Schaer; David (Mamaroneck, NY), Wolchok; Jedd David (New York, NY), Merghoub; Taha (Jersey City, NJ), Savitsky; David Adam (Boxford, MA), Wilson; Nicholas Stuart (San Carlos, CA)
Assignee: AGENUS INC. (Lexington, MA) LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (Zurich, CH) MEMORIAL SLOAN KETTERING CANCER CENTER (New York, NY)
Application Number:15/166,305
Patent Claims:see list of patent claims

Details for Patent 10,144,779

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26 ➤ Sign Up AGENUS INC. (Lexington, MA) LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (Zurich, CH) MEMORIAL SLOAN KETTERING CANCER CENTER (New York, NY) 2035-05-29 RX search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26 ➤ Sign Up AGENUS INC. (Lexington, MA) LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (Zurich, CH) MEMORIAL SLOAN KETTERING CANCER CENTER (New York, NY) 2035-05-29 RX search
Merck Sharp Dohme KEYTRUDA pembrolizumab POWDER, FOR INJECTION SOLUTION, LYOPHILIZED POWDER 125514 001 2014-09-04 ➤ Sign Up AGENUS INC. (Lexington, MA) LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (Zurich, CH) MEMORIAL SLOAN KETTERING CANCER CENTER (New York, NY) 2035-05-29 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Harvard Business School
Argus Health
Merck
Federal Trade Commission
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.